老年重型再生障碍性贫血患者免疫抑制治疗的安全性与疗效
该研究回顾性分析了两项前瞻性临床试验中245例初治重型再生障碍性贫血患者,比较≥60岁与<60岁患者接受抗胸腺细胞球蛋白联合环孢素±艾曲泊帕免疫抑制治疗的安全性;老年患者严重不良事件、ICU入住及住院时间与年轻患者相似,但心脏事件更常见,长期总生存更差、复发和克隆演化更多,然而治疗有效者生存相似。
要点
- 老年患者严重不良事件、ICU入住及住院时间与年轻患者相似。
- 老年患者免疫抑制治疗相关心脏事件更常见,但无死亡。
- 老年患者长期总生存更差、复发和克隆演化更多,但治疗有效者生存相似。
核心结论
- 老年重型再生障碍性贫血患者接受免疫抑制治疗的严重不良事件频率与年轻患者相似,心脏事件更常见但未导致死亡。
- 老年患者长期总生存更差、复发和克隆演化更多,但免疫抑制治疗有效者生存与年轻患者相似。
- 疾病相关因素和难治性疾病治疗选择有限可能是老年患者预后较差的原因,而非 upfront 免疫抑制治疗的并发症。
- 作者认为免疫抑制治疗应作为大多数老年重型再生障碍性贫血患者的一线治疗。
研究设计与样本
- 回顾性分析两项前瞻性免疫抑制治疗临床试验中初治重型再生障碍性贫血患者的数据。
- 纳入245例≥18岁接受抗胸腺细胞球蛋白联合环孢素±艾曲泊帕治疗的患者,其中54例≥60岁,191例<60岁。
- 评估治疗前基线特征和合并症作为治疗相关并发症的预测因素。
主要发现
- 老年患者严重不良事件频率、ICU入住率和住院时间与年轻患者相似。
- 老年患者免疫抑制治疗相关心脏事件频率更高,但无死亡。
- 老年患者长期总生存更差,免疫抑制治疗后复发和克隆演化更多。
- 免疫抑制治疗有效的老年患者在中位随访时生存与年轻患者相似。
临床怎么用
- 作者认为免疫抑制治疗应作为大多数老年重型再生障碍性贫血患者的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uncertainty remains regarding the safety and tolerability of immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine (CSA) in older patients. We retrospectively analysed two prospective clinical trials of IST in treatment-naïve severe aplastic anaemia (SAA) to assess safety in older compared to younger patients. Patients ≥18 years of age who had received IST with ATG and CSA +/- eltrombopag (EPAG) were included. Pre-treatment baseline characteristics and co-morbidities were assessed as predictors of therapy-related complications in younger (<60 years) versus older (≥60 years) patients. Out of 245 eligible patients, 54 were older and 191 were younger. Older patients had a similar frequency of SAEs, ICU admissions and hospital length of stay compared to younger patients. Older patients had a higher frequency of cardiac events related to IST, but none resulted in death. Older patients had worse long-term overall survival, and more relapse and clonal evolution post-IST. However, older patients who responded to IST had a similar survival at a median follow-up to younger patients. Disease-related factors and limited therapeutic options in refractory disease likely contribute to poorer outcomes in older patients, not complications of upfront IST. Therefore, IST should be considered first-line therapy for most older SAA patients.
引用
- Prabahran A, Durrani J, Coelho-Da Silva J, et al. Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. Br J Haematol. 2024. PMID: 39021060. doi:10.1111/bjh.19648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。